Back to Authors

Squirewell, Edwin J.

Mayo Clinic

Mayo Clinic

Citations 2

Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix
Heim, Joel B. , Squirewell, Edwin J., Neu, Ancilla, Zocher, Georg , Sominidi‐Damodaran, Sindhuja , Wyles, Saranya P. , Nikolova, Ekaterina , Behrendt, Nille, Saunte, Ditte Marie Lindhardt , Lock‐Andersen, Jørgen, Gaonkar, Krutika S. , Yan, Huihuang , Deursen, Jan van, Sprangers, Remco , Stehle, Thilo , Böttcher, Ralph T. , Lee, Jeong‐Heon , Ördög, Tamás , Meves, Alexander , van Deursen, Jan, Meves, Alexander , Sarkaria, Jann N. , Krendel, Mira , Lee, Jeong-Heon , Heim, Joel B

Proceedings of the National Academy of Sciences | March 27, 2017 | Volume: 114 | Issue: 15 | Pages: 3933-3938

10.1073/pnas.1614894114 Get It

Significance Focal adhesion kinase (FAK) is an intensely studied protein involved in many medically relevant biological processes, including cancer. Despite the large interest in FAK, a promising strategy to target FAK therapeutically is elusive. Here, we show that a region within the FAK protein that contains autophosphorylation site tyrosine (Y) 397 is essential for FAK activity in vivo. Myosin-1E (MYO1E), an actin-dependent molecular motor protein, directly interacts with FAK to induce Y397 autophosphorylation, which, in turn, causes changes in gene expression commonly observed in aggressive cancer. Our findings are significant because they further delineate FAK function in vivo and identify the MYO1E–FAK interaction as a possible Achilles’ heel for cancer.
Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Meves, Alexander , Nikolova, Ekaterina , Heim, Joel B. , Squirewell, Edwin J., Cappel, Mark A. , Pittelkow, Mark R. , Otley, Clark C. , Behrendt, Nille, Saunte, Ditte Marie Lindhardt , Lock‐Andersen, Jørgen, Schenck, Louis A., Weaver, Amy L. , Saunte, Ditte M, Suman, Vera J. , Heim, Joel B

Journal of Clinical Oncology | July 7, 2015 | Volume: 33 | Issue: 23 | Pages: 2509-2515

10.1200/jco.2014.60.7002 Get It

Purpose Less than 20% of patients with melanoma who undergo sentinel lymph node (SLN) biopsy based on American Society of Clinical Oncology/Society of Surgical Oncology recommendations are SLN positive. We present a multi-institutional study to discover new molecular risk factors associated with SLN positivity in thin and intermediate-thickness melanoma. Patients and Methods Gene clusters with functional roles in melanoma metastasis were discovered by next-generation sequencing and validated by quantitative polymerase chain reaction using a discovery set of 73 benign nevi, 76 primary cutaneous melanoma, and 11 in-transit melanoma metastases. We then used polymerase chain reaction to quantify gene expression in a model development cohort of 360 consecutive thin and intermediate-thickness melanomas and a validation cohort of 146 melanomas. Outcome of interest was SLN biopsy metastasis within 90 days of melanoma diagnosis. Logic and logistic regression analyses were used to develop a model for the likelihood of SLN metastasis from molecular, clinical, and histologic variables. Results ITGB3, LAMB1, PLAT, and TP53 expression were associated with SLN metastasis. The predictive ability of a model that included these molecular variables in combination with clinicopathologic variables (patient age, Breslow depth, and tumor ulceration) was significantly greater than a model that only considered clinicopathologic variables and also performed well in the validation cohort (area under the curve, 0.93; 95% CI, 0.87 to 0.97; false-positive and false-negative rates of 22% and 0%, respectively, using a 10% cutoff for predicted SLN metastasis risk). Conclusion The addition of cell adhesion–linked gene expression variables to clinicopathologic variables improves the identification of patients with SLN metastases within 90 days of melanoma diagnosis.